CVS Health Q3 2024 Earnings Report
Key Takeaways
CVS Health's total revenues for the third quarter increased by 6.3% to $95.4 billion. GAAP diluted EPS was $0.07, and adjusted EPS was $1.09. The results were impacted by charges related to premium deficiency reserves in the Health Care Benefits segment.
Total revenues increased by 6.3% compared to the prior year, reaching $95.4 billion.
GAAP diluted EPS was $0.07, and adjusted EPS was $1.09.
Health Care Benefits segment recorded premium deficiency reserves of approximately $1.1 billion.
Strong performance was noted in the Health Services and Pharmacy & Consumer Wellness segments.
CVS Health
CVS Health
CVS Health Revenue by Segment
Forward Guidance
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, the information under the headings “CEO Commentary” and “Financial Results Summary” and the information included in the reconciliations and endnotes. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission (“SEC”) filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024 and our Current Reports on Form 8-K.
Revenue & Expenses
Visualization of income flow from segment revenue to net income